Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
IFOM ETS - The AIRC Institute of Molecular Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Vanderbilt University Medical Center
BeOne Medicines
Amgen
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC
Dartmouth-Hitchcock Medical Center
University of California, San Francisco
National Cancer Center Hospital East
Milton S. Hershey Medical Center
Daiichi Sankyo
University of Kansas Medical Center
Pierre Fabre Medicament
Ohio State University Comprehensive Cancer Center
Freenome Holdings Inc.
Bristol-Myers Squibb
NantCell, Inc.
Massachusetts General Hospital
Alaska Native Tribal Health Consortium
Vedanta Biosciences, Inc.
Eisai Inc.
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Dartmouth-Hitchcock Medical Center
New Mexico Cancer Research Alliance
Sanofi
Merck Sharp & Dohme LLC
Elicio Therapeutics
University of California, San Diego
Duke University
Washington State University
Palleon Pharmaceuticals, Inc.
Virginia Commonwealth University
NYU Langone Health
OHSU Knight Cancer Institute
Incyte Corporation
Incyte Corporation
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Trishula Therapeutics, Inc.
Institut Bergonié
OHSU Knight Cancer Institute
University of Hawaii
Academic and Community Cancer Research United
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nektar Therapeutics
Hoffmann-La Roche
Pfizer